Home / Market News / $BSEM
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

BioStem Technologies Reports Third Quarter 2026 Financial Results and Raises Full-Year Revenue Guidance

Nov 13, 2026, 2:22 PM UTC · Primary ticker $BSEM

BioStem Technologies reported Q3 2026 results with $7.6M revenue and a $11.4M net loss, while raising its full-year revenue guidance. The increased guidance and sequential hospital revenue growth are positive signals, but the net loss remains a concern. The commencement of in-house production in H1 2027 could improve future margins.

BioStem Technologies announced its Q3 2026 financial results, reporting $7.6 million in net revenue and a GAAP net loss of $11.4 million. The company raised its full-year 2026 revenue guidance to $28 million to $29 million, up from $26 million to $29 million, indicating management's increased confidence in future sales. This guidance raise, coupled with sequential growth in hospital revenue and increased multi-product line customers, suggests improving operational performance. The upcoming in-house production of key product lines in H1 2027 is a long-term positive, potentially leading to better cost control and supply chain efficiency. For traders, the raised guidance presents a short-term positive catalyst, but the significant net loss remains a key risk, highlighting the company's path to profitability.

$BSEM positive Raised revenue guidance, sequential hospital revenue growth
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.